-
Oct 30, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
European Commission Imposes Heavy Fine on Teva for Misuse of Patent System and Disparaging Rival’s Product*Today, the European Commission (the Commission) fined Teva EUR 462.6 million for abusing its dominant position to delay the market entry of rival medicines for the treatment of relapsing forms of multiple sclerosis (see, attached press release and statement). The Commission established that Teva artificially delayed competition and extended the patent protection of its product Copaxone®...
-
Oct 30, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
European Commission Imposes Heavy Fine on Teva for Misuse of Patent System and Disparaging Rival’s Product*Today, the European Commission (the Commission) fined Teva EUR 462.6 million for abusing its dominant position to delay the market entry of rival medicines for the treatment of relapsing forms of multiple sclerosis (see, attached press release and statement). The Commission established that Teva artificially delayed competition and extended the patent protection of its product Copaxone®...
-
Oct 9, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
Previous article Next article Share on | The Swiss Competition Authority ( Competition Commission or Comco ) indicated today that it terminated its inquiry into patent litigation conducted by Novartis to protect Cosentyx®, a human IgG1 monoclonal antibody indicated for the treatment of several autoimmune diseases, including specific dermatological conditions (see, attached press release in four language versions). Both Comco and the European Commission (the Commission ) had sought to learn...
-
Sep 30, 2024 | 
concurrences.com | Van Bael |Van Hove |Jean-François Bellis |Peter L'Ecluse
Article précédent Article suivant Partager sur | On 30 September 2024, the Federal Public Service Economy published its first annual report (the Report ) on the screening of foreign direct investments ( FDI ) and the operations of the Belgian Interfederal Screening Committee (the ISC ).
-
Sep 4, 2024 | 
concurrences.com | Van Bael |Van Hove |Jean-François Bellis |Peter L'Ecluse
The European Commission (the Commission ) published on 5 September 2024 a report on interim measures used by national competition authorities ( NCAs ) (see, attachment – the IM Report ). When Directive 2019/1 to make NCAs more effective competition law enforcers (the ECN+ Directive ) became law, the Commission promised to come up with an analysis of means to simplify the adoption of interim measures by NCAs. The resulting IM Report discusses the impact of the ECN+ Directive on the power of...
-
Sep 2, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Valérie Lefever
Previous article Next article Share on | Yesterday, the Grand Chamber of the Court of Justice of the European Union (the CJEU ) set aside the judgment in which the General Court ( GC ) had confirmed the competence of the European Commission (the Commission ) to review (and ultimately prohibit) the acquisition of Grail by Illumina and annulled the Commission’s decisions to accept to review this case following referral requests by France and other Member States (CJEU, judgment of 3 September in...
-
Sep 2, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Valérie Lefever
Yesterday, the Grand Chamber of the Court of Justice of the European Union (the CJEU ) set aside the judgment in which the General Court ( GC ) had confirmed the competence of the European Commission (the Commission ) to review (and ultimately prohibit) the acquisition of Grail by Illumina and annulled the Commission’s decisions to accept to review this case following referral requests by France and other Member States (CJEU, judgment of 3 September in Joined Cases C-611/22 P and C-625/22 P...
-
Aug 28, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
The Greek competition authority ( Hellenic Competition Commission or ) announced on 29 August 2024 that it issued a Statement of Objections ( ) against Switzerland-based Novartis and that firm’s Greek subsidiary on account of suspected exclusionary behaviour on the Greek market for the treatment of macular diseases (see, attached press release). The abusive conduct allegedly took place between 2009 and 2017 in two forms: First, Novartis supposedly paid physicians and healthcare inst...
-
Aug 28, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
The Greek competition authority ( Hellenic Competition Commission or ) announced on 29 August 2024 that it issued a Statement of Objections ( ) against Switzerland-based Novartis and that firm’s Greek subsidiary on account of suspected exclusionary behaviour on the Greek market for the treatment of macular diseases (see, attached press release). The abusive conduct allegedly took place between 2009 and 2017 in two forms: First, Novartis supposedly paid physicians and healthcare inst...
-
Aug 28, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
The Greek competition authority ( Hellenic Competition Commission or ) announced on 29 August 2024 that it issued a Statement of Objections ( ) against Switzerland-based Novartis and that firm’s Greek subsidiary on account of suspected exclusionary behaviour on the Greek market for the treatment of macular diseases (see, attached press release). The abusive conduct allegedly took place between 2009 and 2017 in two forms: First, Novartis supposedly paid physicians and healthcare inst...
